De-escalating strategy for antibiotic treatment in intensive care unit;Indication, intérêts et limites de la désescalade antibiotique en réanimation

Reanimation

Volumn 15, Issue 3, 2006, Pages 159-167

  Leroy, O ^a   Boussekey, N ^a   Georges, H ^a  

^a Service de Réanimation Médicale et Maladies Infectieuses Hôpital Chatiliez Rue du Président Coty   (France)

Author keywords

Antimicrobial treatment; De escalation antibiotic therapy; Hospital acquired infections; Pneumonia; Prognosis

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC THERAPY; BACTEREMIA; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; MENINGITIS; MORTALITY; PERITONITIS; PNEUMONIA; RESUSCITATION; SHORT SURVEY;

EID: 33646777427     PISSN: 16240693     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.reaurg.2006.02.001     Document Type: Short Survey

References (60)

1. Kollef M.H., and Micek S.T. Strategies to prevent antimicrobial resistance in the intensive care unit. Crit. Care Med. 33 (2005) 1845-1853
2. Alberti C., Brun-Buisson C., Burchardi H., Martin C., Goodman S., Artigas A., et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med. 28 (2002) 108-121
3. Kollef M.H., Sherman G., Ward S., and Fraser V.J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115 (1999) 462-474
4. Garnacho-Montero J., Garcia-Garmendia J.L., Barrero-Almodovar A., Jimenez-Jimenez F.J., Perez-Paredes C., and Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit. Care Med. 31 (2003) 2742-2751
5. MacArthur R.D., Miller M., Albertson T., Panacek E., Johnson D., Teoh L., et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin. Infect. Dis. 38 (2004) 284-288
6. Zaidi M., Sifuentes-Osornio J., Rolon A.L., Vazquez G., Rosado R., Sanchez M., et al. Inadequate therapy and antibiotic resistance. Risk factors for mortality in the intensive care unit. Arch. Med. Res. 33 (2002) 290-294
7. Leone M., Bourgoin A., Cambon S., Dubuc M., Albanese J., and Martin C. Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. Crit. Care Med. 31 (2003) 462-467
8. Fine M.J., Auble T.E., Yealy D.M., Hanusa B.H., Weissfeld L.A., Singer D.E., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 336 (1997) 243-250
9. Roson B., Carratala J., Fernandez-Sabe N., Tubau F., Manresa F., and Gudiol F. Causes and factors associated with early failure in hospitalised patients with community-acquired pneumonia. Arch. Intern. Med. 164 (2004) 502-508
10. Torres A., Serra-Batlles J., Ferrer A., Jimenez P., Celis R., Cobo E., et al. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am. Rev. Respir. Dis. 144 (1991) 312-318
11. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-acquired pneumonia study group. Intensive Care Med. 22 (1996) 387-394
12. Rello J., Gallego M., Mariscal D., Sonora R., and Valles J. The value of routine microbial investigation in ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 156 (1997) 196-200
13. Luna C.M., Vujacich P., Niederman M.S., Vay C., Gherardi C., Matera J., et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 111 (1997) 676-685
14. Kollef M.H., and Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 113 (1998) 412-420
15. Bercault N., and Boulain T. Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: a prospective case-control study. Crit. Care Med. 29 (2001) 2303-2309
16. Dupont H., Mentec H., Sollet J.P., and Bleichner G. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med. 27 (2001) 355-362
17. Leroy O., Meybeck A., d'Escrivan T., Devos P., Kipnis E., and Georges H. Impact of adequacy of initial antimicrobial therapy on the prognosis of patients with ventilator-associated pneumonia. Intensive Care Med. 29 (2003) 2170-2173
18. Dupont H., Montravers P., Gauzit R., Veber B., Pouriat J.L., and Martin C. Club d'infectiologie en anesthésie-réanimation. Outcome of postoperative pneumonia in the EOLE study. Intensive Care Med. 29 (2003) 179-188
19. Clec'h C., Timsit J.F., De Lassence A., Azoulay E., Alberti C., Garrouste-Orgeas M., et al. Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: influence of disease severity. Intensive Care Med. 30 (2004) 1327-1333
20. Fowler R.A., Flavin K.E., Barr J., Weinacker A.B., Parsonnet J., and Gould M.K. Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia. Chest 123 (2003) 835-844
21. Moine P., Timsit J.F., De Lassence A., Troche G., Fosse J.P., Alberti C., et al. OUTCOMEREA study group. Mortality associated with late-onset pneumonia in the intensive care unit: results of a multicenter cohort study. Intensive Care Med. 28 (2002) 154-163
22. Mueller E.W., Hanes S.D., Croce M.A., Wood G.C., Boucher B.A., and Fabian T.C. Effect from multiple episodes of inadequate empiric antibiotic therapy for ventilator-associated pneumonia on morbidity and mortality among critically ill trauma patients. J. Trauma 58 (2005) 94-101
23. Iregui M., Ward S., Sherman G., Fraser V.J., and Kollef M.H. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 122 (2002) 262-268
24. Ibrahim E.H., Sherman G., Ward S., Fraser V.J., and Kollef M.H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118 (2000) 146-155
25. Valles J., Rello J., Ochagavia A., Garnacho J., and Alcala M.A. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest 123 (2003) 1615-1624
26. Zaragoza R., Artero A., Camarena J.J., Sancho S., Gonzalez R., and Nogueira J.M. The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin. Microbiol. Infect. 9 (2003) 412-418
27. Leibovici L., Shraga I., Drucker M., Konigsberger H., Samra Z., and Pitlik S.D. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J. Intern. Med. 244 (1998) 379-386
28. Harbarth S., Garbino J., Pugin J., Romand J.A., Lew D., and Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am. J. Med. 115 (2003) 529-535
29. Weinstein M.P., Towns M.L., Quartey S.M., Mirrett S., Reimer L.G., Parmigiani G., et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin. Infect. Dis. 24 (1997) 584-602
30. Lodise T.P., McKinnon P.S., Swiderski L., and Rybak M.J. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin. Infect. Dis. 36 (2003) 1418-1423
31. Kang C.I., Kim S.H., Kim H.B., Park S.W., Choe Y.J., Oh M.D., et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin. Infect. Dis. 37 (2003) 745-751
32. Morrell M., Fraser V.J., and Kollef M.H. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 49 (2005) 3640-3645
33. Bochud P.Y., Glauser M.P., and Calandra T. Antibiotics in sepsis. Intensive Care Med. 27 (2001) S33-S48
34. Mosdell D.M., Morris D.M., Voltura A., Pitcher D.E., Twiest M.W., Milne R.L., et al. Antibiotic treatment for surgical peritonitis. Ann. Surg. 214 (1991) 543-549
35. Christou N.V., Turgeon P., Wassef R., Rotstein O., Bohnen J., and Potvin M. Management of intra-abdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. The Canadian intra-abdominal infection study group. Arch. Surg. 131 (1996) 1193-1201
36. Montravers P., Gauzit R., Muller C., Marmuse J.P., Fichelle A., and Desmonts J.M. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intra-abdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin. Infect. Dis. 23 (1996) 486-494
37. Proulx N., Frechette D., Toye B., Chan J., and Kravcik S. Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. QJM 98 (2005) 291-298
38. Kollef M.H., and Fraser V.J. Antibiotic resistance in the intensive care unit. Ann. Intern. Med. 134 (2001) 298-314
39. Salgado C.D., O'grady N., and Farr B.M. Prevention and control of antimicrobial-resistant infections in intensive care patients. Crit. Care Med. 33 (2005) 2373-2382
40. Safdar N., and Maki D.G. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, Enterococcus, Gram-negative bacilli, Clostridium difficile, and Candida. Ann. Intern. Med. 136 (2002) 834-844
41. Paterson D.L. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin. Infect. Dis. 38 Suppl 4 (2004) S341-S345
42. Pedersen G., Schonheyder H.C., Steffensen F.H., and Sorensen H.T. Risk of resistance related to antibiotic use before admission in patients with community-acquired bacteraemia. J. Antimicrob. Chemother. 43 (1999) 119-126
43. Harbarth S., Harris A.D., Carmeli Y., and Samore M.H. Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in Gram-negative bacilli. Clin. Infect. Dis. 33 (2001) 1462-1468
44. Nseir S., Di Pompeo C., Soubrier S., Delour P., Lenci H., Roussel-Delvallez M., et al. First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit. Crit. Care Med. 33 (2005) 283-289
45. Trouillet J.L., Chastre J., Vuagnat A., Joly-Guillou M.L., Combaux D., Dombret M.C., et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am. J. Respir. Crit. Care Med. 157 (1998) 531-539
46. Kollef M.H. Optimizing antibiotic therapy in the intensive care unit setting. Crit. Care 5 (2001) 189-195
47. Kollef M.H. Gram negative bacterial resistance: evolving patterns and treatment paradigms. Clin. Infect. Dis. 40 Suppl 2 (2005) S85-S88
48. Kollef M.H. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalised patients. Clin. Infect. Dis. 31 Suppl 4 (2000) S131-S138
49. Rello J., Vidaur L., Sandiumenge A., Rodriguez A., Gualis B., Boque C., et al. De-escalation therapy in ventilator-associated pneumonia. Crit. Care Med. 32 (2004) 2183-2190
50. Conférence de Consensus de la SPILF. Les méningites purulentes communautaires. Med. Mal. Infect. 26 (1996) 944-951
51. Hoffken G., and Niederman M.S. Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 122 (2002) 2183-2196
52. American Thoracic Society Documents. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171 (2005) 388-416
53. Leroy O., Girardie P., Yazdanpanah Y., Georges H., Alfandari S., Sanders V., et al. Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens. Eur. Respir. J. 20 (2002) 432-439
54. Chastre J., Wolff M., Fagon J.Y., Chevret S., Thomas F., Wermert D., et al., PneumA Trial Group. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomised trial. JAMA 290 (2003) 2588-2598
55. Kollef M.H., and Kollef K.E. Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results. Chest 128 (2005) 2706-2713
56. Chastre J., and Fagon J.Y. Ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 165 (2002) 867-903
57. Dennesen P.J., van der Ven A.J., Kessels A.G., Ramsay G., and Bonten M.J. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 163 (2001) 1371-1375
58. Luna C.M., Blanzaco D., Niederman M.S., Matarucco W., Baredes N.C., Desmery P., et al. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit. Care Med. 31 (2003) 676-682
59. Vidaur L., Gualis B., Rodriguez A., Ramirez R., Sandiumenge A., Sirgo G., et al. Clinical resolution in patients with suspicion of ventilator-associated pneumonia: a cohort study comparing patients with and without acute respiratory distress syndrome. Crit. Care Med. 33 (2005) 1248-1253
60. Weiss K., and Tillotson G.S. The controversy of combination vs monotherapy in the treatment of hospitalised community-acquired pneumonia. Chest 128 (2005) 940-946